The estimated Net Worth of Robert Iannone is at least $7.79 millió dollars as of 9 December 2022. Robert Iannone owns over 1,844 units of Jazz Pharmaceuticals plc stock worth over $3,817,901 and over the last 6 years he sold JAZZ stock worth over $279,440. In addition, he makes $3,693,560 as Executive Vice President és Research and Development at Jazz Pharmaceuticals plc.
Robert has made over 1 trades of the Jazz Pharmaceuticals plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,844 units of JAZZ stock worth $279,440 on 9 December 2022.
The largest trade he's ever made was selling 1,844 units of Jazz Pharmaceuticals plc stock on 9 December 2022 worth over $279,440. On average, Robert trades about 71 units every 0 days since 2018. As of 9 December 2022 he still owns at least 36,316 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Robert Iannone stock trades at the bottom of the page.
Dr. Robert Iannone M.D. serves as Executive Vice President, Research and Development of the Company. Dr. Iannone served as Head of Research and Development and Chief Medical Officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of Senior Vice President and Head of Immuno-oncology, Global Medicines Development and the Global Products Vice President at AstraZeneca plc, a global science-led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as Executive Director and Section Head of Oncology Clinical Development. From 2001 to 2004, he served as Assistant Professor of Pediatrics and from 2004 to 2012 as Adjunct Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, since January 2020 and on the Cancer Steering Committee of the Foundation for the National Institutes of Health since 2011. Dr. Iannone received a B.S. from The Catholic University of America, an M.D. from Yale University and an M.S.C.E. from University of Pennsylvania and completed his residency in Pediatrics and fellowship in Pediatric Hematology-Oncology at Johns Hopkins University.
As the Executive Vice President és Research and Development of Jazz Pharmaceuticals plc, the total compensation of Robert Iannone at Jazz Pharmaceuticals plc is $3,693,560. There are 2 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
Robert Iannone is 53, he's been the Executive Vice President és Research and Development of Jazz Pharmaceuticals plc since 2019. There are 17 older and 9 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright és Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: